JP2019526595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526595A5 JP2019526595A5 JP2019512763A JP2019512763A JP2019526595A5 JP 2019526595 A5 JP2019526595 A5 JP 2019526595A5 JP 2019512763 A JP2019512763 A JP 2019512763A JP 2019512763 A JP2019512763 A JP 2019512763A JP 2019526595 A5 JP2019526595 A5 JP 2019526595A5
- Authority
- JP
- Japan
- Prior art keywords
- cti
- antibody
- kinase
- delta inhibitor
- ubrituximab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385723P | 2016-09-09 | 2016-09-09 | |
| US62/385,723 | 2016-09-09 | ||
| PCT/US2017/050825 WO2018049263A1 (en) | 2016-09-09 | 2017-09-08 | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526595A JP2019526595A (ja) | 2019-09-19 |
| JP2019526595A5 true JP2019526595A5 (enExample) | 2020-10-15 |
Family
ID=59969229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512763A Pending JP2019526595A (ja) | 2016-09-09 | 2017-09-08 | 血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190247399A1 (enExample) |
| EP (1) | EP3509634A1 (enExample) |
| JP (1) | JP2019526595A (enExample) |
| KR (1) | KR20190068521A (enExample) |
| CN (1) | CN110191720A (enExample) |
| AU (1) | AU2017322501A1 (enExample) |
| BR (1) | BR112019004185A2 (enExample) |
| CA (1) | CA3035976A1 (enExample) |
| CL (1) | CL2019000585A1 (enExample) |
| EA (1) | EA201990374A1 (enExample) |
| IL (1) | IL265194A (enExample) |
| MX (1) | MX2019002728A (enExample) |
| WO (1) | WO2018049263A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7148414B2 (ja) * | 2016-06-29 | 2022-10-05 | チェックポイント セラピューティクス，インコーポレイテッド | Ｐｄ－ｌ１特異的抗体およびそれを使用する方法 |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020191022A1 (en) * | 2019-03-18 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 9x |
| US12628858B2 (en) | 2019-03-21 | 2026-05-19 | Cornell University | Therapy for colorectal and small intestine cancers |
| KR20220035169A (ko) * | 2019-07-15 | 2022-03-21 | 존슨 맛쎄이 퍼블릭 리미티드 컴파니 | 비정질 움브랄리십 모노토실레이트 |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| CN117222413A (zh) * | 2021-02-10 | 2023-12-12 | 同润生物医药(上海)有限公司 | 治疗肿瘤的方法和组合 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CA3252868A1 (en) * | 2022-02-28 | 2023-08-31 | Jasper Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE DEPLOYMENT OF DISEASED HEMATOPOIETIC STEM CELLS |
| CN115141092A (zh) * | 2022-07-27 | 2022-10-04 | 诚达药业股份有限公司 | 一种抗淋巴瘤药物相关化合物的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| LT2496567T (lt) | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Nauji benzopirano kinazės moduliatoriai |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| WO2013022091A1 (ja) * | 2011-08-11 | 2013-02-14 | 小野薬品工業株式会社 | Ｐｄ－１アゴニストからなる自己免疫疾患治療剤 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| PT2870157T (pt) | 2012-07-04 | 2017-11-27 | Rhizen Pharmaceuticals S A | Inibidores seletivos de delta pi3k |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| KR102185175B1 (ko) * | 2012-11-02 | 2020-12-02 | 티지 쎄라퓨틱스, 인코포레이티드 | 항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물 |
| AU2015265542B2 (en) | 2014-05-27 | 2019-05-09 | Rhizen Pharmaceuticals Sa | Improved forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
| RS63364B1 (sr) * | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora |
| EP3191126B1 (en) * | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
-
2017
- 2017-09-08 US US16/331,407 patent/US20190247399A1/en not_active Abandoned
- 2017-09-08 EP EP17772801.1A patent/EP3509634A1/en not_active Withdrawn
- 2017-09-08 CA CA3035976A patent/CA3035976A1/en not_active Abandoned
- 2017-09-08 CN CN201780066399.5A patent/CN110191720A/zh active Pending
- 2017-09-08 JP JP2019512763A patent/JP2019526595A/ja active Pending
- 2017-09-08 MX MX2019002728A patent/MX2019002728A/es unknown
- 2017-09-08 WO PCT/US2017/050825 patent/WO2018049263A1/en not_active Ceased
- 2017-09-08 BR BR112019004185A patent/BR112019004185A2/pt not_active IP Right Cessation
- 2017-09-08 AU AU2017322501A patent/AU2017322501A1/en not_active Abandoned
- 2017-09-08 KR KR1020197008508A patent/KR20190068521A/ko not_active Ceased
- 2017-09-08 EA EA201990374A patent/EA201990374A1/ru unknown
-
2019
- 2019-03-06 IL IL265194A patent/IL265194A/en unknown
- 2019-03-07 CL CL2019000585A patent/CL2019000585A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagelkerke et al. | Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy | |
| JP2019506403A5 (enExample) | ||
| KR102945599B1 (ko) | 암 치료를 위한 ch5126766과 조합된 vs-6063 | |
| US12447150B2 (en) | Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy | |
| JP2020505433A5 (enExample) | ||
| JP2019517485A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| JP2012509889A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| JP2011529968A5 (enExample) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2019508433A (ja) | Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法 | |
| JP2017536408A5 (enExample) | ||
| JPWO2020111018A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JP2022523045A5 (enExample) | ||
| JP2018519300A5 (enExample) | ||
| JP2021522246A5 (enExample) | ||
| JP2025511402A5 (enExample) | ||
| Vansteenkiste et al. | A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer | |
| CA3242136A1 (en) | Clinical formulations of anti-tigit antibodies | |
| JP2024535880A5 (enExample) |